Due to the use of a systemic pharmacologic inhibitor of Cpt1a in the mouse models, infection-related outcomes cannot be specifically attributed to impaired neutrophil trafficking as it is likely that the effects of Cpt1a inhibition in non-neutrophils impact the course of infection. This evidence concerns the gene CPT1A and infection.